Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Atopic Dermatitis and Skin of Color (ADmirable)
NCT05372419Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Primary endpoint: Eczema Area and Severity Index 75 at 16 weeks. Started Jan 2023; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05372419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372419.